September 9th, 2015 - Terumo Corporation （Headquarters: Shibuya-ku, Tokyo, Japan; President: Yutaro Shintaku） and Quirem Medical B.V., a commercial stage Dutch medical technology company that focuses on radioembolization, today announced that Terumo has made an equity investments in Quirem Medical.
Quirem Medical develops QuiremSpheres, next generation microspheres for the radioembolization treatment of liver cancer, which was developed by the University Medical Center （UMC） Utrecht, and received the European CE mark for quality and safety earlier this year.
Peter Coenen, president of Terumo Europe Interventional Systems, commented: "QuiremSpheres could be a good fit with the product portfolio offered by Terumo to interventional oncologists and interventional doctors in their treatment of cancer patients."
Jan Sigger, CEO of Quirem Medical, commented: "We consider our holmium microspheres as 'the next generation microspheres for radioembolization', as they can be visualized by both MRI scans and SPECT-CT, allowing customized treatment for each individual patient. We are confident that the investment by Terumo will accelerate our global expansion, reflecting our ambition to make our technology available to patients around the world."
Professor Maurice van den Bosch, head of Radiology University Centre Utrecht, commented: "We congratulate Quirem Medical and Terumo with their strategic partnership. Over the last 15 years the Holmium microsphere technology, on which the QuiremSpheres are based, have been successfully developed within the University Medical Centre Utrecht. I am confident that our strategic collaboration with Quirem Medical will strongly benefit from the additional capabilities invested by Terumo".
About Quirem Medical
Quirem Medical is an emerging medical device company with a mission to develop the next generation microspheres for targeted interventional oncology solutions.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.